Bioanalysis

  • Bioanalysis
  • Bioanalytical Platform Selection for Your Molecule

    Renowned for our expertise with LC-MS/MS and Ligand Binding platforms, Altasciences can help you expedite your research goals by efficiently determining which bioanalytical platform is most appropriate for your molecule― from discovery, to preclinical safety testing, to first-in-human trials, and beyond.

    With Altasciences' in-house database of over 680 validated assays, as well as the ability to provide customized workflows and methods using advanced instrumentation and various bioanalytical platforms, we can help you make the right decision.

    CONTACT US

    Bioanalytical Expertise in ASO Quantification

    The development of antisense oligonucleotides (ASOs) is showing promise in therapeutic applications for a number of diseases, both neurological and non-neurological. The accurate quantification of ASOs in complex biological tissues requires robust and sensitive bioanalytical assays that minimize interference, an area in which Altasciences has significant expertise.

    In this issue of The Altascientist we provide an overview of the evolving ASO therapeutic approach, and present two case studies demonstrating our capabilities in the field.

    How Can We Help

    Dear Partners,

    Like me, you probably have an inbox full of messages about steps being taken to avoid further contamination on company premises, at home, and worldwide. First, let me assure you that COVID-19 has our full attention here at Altasciences, and the safety of our employees, clients, and study participants will always be our top priority.

    Second, know that many here at Altasciences are accustomed to working in unprecedented situations and making the right and, often difficult, decisions. We continue to focus on helping you bring your drugs to market and providing you the quality and timelines you have come to expect from us.

    In line with the current public health and government sources of information, we have updated and are continuously reviewing our business continuity plan to enable proactive, flexible, and dependable delivery of our commitments, some of which includes:

    • Avoiding all non-essential travel and implementing a 14-day quarantine for returning travellers or staff with cold or flu-like symptoms.
    • Providing flexible work arrangements to our employees, including teleworking and a variety of schedules to ensure social distancing; in fact, a lot of our employees already work remotely, so we have the technologies and processes in place needed to provide a virtual service effectively and seamlessly regardless of location. The same tools can be used for remote monitoring of your studies.
    • Holding internal and external meetings via video and audio conferencing, also to ensure social distancing.
    • Our intention is to ensure preclinical and clinical studies proceed according to plan, and that site staff, patients and test animals are safe. We have provided guidance for risk-based and remote monitoring wherever possible.

    At Altasciences, we care about your studies and deliverables. We have the team and safety measures in place to ensure your studies continue. These are challenging times, but we feel confident that as a company and research community, we can get through this together.

    Please let me know how we can help. I am here to personally discuss any of your questions or concerns. If there are any significant changes to the way we do business in the upcoming weeks, I will personally ensure you are informed.

    Be well,

    Chris Perkin
    CEO, Altasciences

    Analysis of Fenfluramine and Norfenfluramine in Mouse Brain and Cerebellum by Liquid Chromatography Tandem Mass Spectrometry using a Novel Solid-Supported Liquid Extraction

    Answers to your questions on the development of biologics and biosimilars

     

    Renowned for our full-service offering, we often get asked — how does Altasciences manage the development process for biologics and biosimilars so seamlessly from the required preclinical studies to first-in-human trials?

    Bioanalytical Solutions Throughout the Drug Development Continuum

    Leverage Altasciences' preclinical and clinical bioanalytical expertise to accelerate your drug development programs. We have been delivering premium bioanalytical services to global pharma and biotech companies for over 25 years. We take pride in the diversity, expertise, and bandwidth of our scientific team, many of whom are industry-recognized bioanalytical subject matter experts. From de novo development to rugged and robust validated assays, you can rely on our experience to help you reach your milestones.

    With Altasciences, you can rest easy knowing that your studies are conducted in our state-of-the art laboratories, either in the U.S. or Canada, whether for small or large molecule programs, using ligand binding or mass spectrometry platforms.

    In addition, each bioanalytical project is assigned a scientist with whom you can communicate directly, for efficient and effective project progression.

    Detection of Peripheral Blood Foxp3+ Regulatory T Cell Population in a Preclinical Setting

    Translatability of Non-Human Primate Cytokine Data to In-Life Parameters in Nonclinical

    Quantitative Bioanalysis of Rituximab and Reditux for Biosimilarity Assessment: Comparing Triple Quadrupole and Hybrid Time-of-Flight Platforms

    A Sensitive LC-HRMS Method for the Quantitation of Dystrophin in Human Muscle Tissue

    Subscribe to Bioanalysis